1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar ...
11 November 2024 - Medicare Advantage patients in the last year of life were far more likely to switch to traditional ...
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
12 November 2024 - Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients who have ...
12 November 2024 - Abeona Therapeutics today announced that the US FDA has accepted for review Abeona’s resubmission of its ...
12 November 2024 - GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected ...
13 November 2024 - Intercept Pharmaceuticals today announced that the US FDA has issued a complete response letter that addresses ...
12 November 2024 - Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 Phase 2 trial and supported ...
12 November 2024 - PHARMAC has decided to fund the medicine empagliflozin for thousands of people with a type of ...
11 November 2024 - FDA sets PDUFA action date of 28 June 2025. ...
8 November 2024 - Neurotech Pharmaceuticals today announced that the US FDA has extended the PDUFA goal date by three months ...
11 November 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
11 November 2024 - The breakthrough therapy designation for investigational nipocalimab in Sjögren’s disease, a prevalent autoantibody disease with no approved ...
6 November 2024 - Erdafitinib is the first and only bladder cancer therapy that targets FGFR3 alterations and has been ...
11 November 2024 - PHARMAC will make two changes for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy this ...
10 November 2024 - Australian mums and their newborn babies will have free access to the best and most comprehensive ...